- Home
- BNTC vs IMAB Comparison
BNTC vs IMAB Comparison
Compare BNTC & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTC
- IMAB
- Stock Information
- Founded
- BNTC 1995
- IMAB 2014
- Country
- BNTC United States
- IMAB United States
- Employees
- BNTC N/A
- IMAB N/A
- Industry
- BNTC Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BNTC Health Care
- IMAB Health Care
- Exchange
- BNTC Nasdaq
- IMAB Nasdaq
- Market Cap
- BNTC 365.1M
- IMAB 384.6M
- IPO Year
- BNTC N/A
- IMAB 2020
- Fundamental
- Price
- BNTC $13.78
- IMAB $3.64
- Analyst Decision
- BNTC Strong Buy
- IMAB Strong Buy
- Analyst Count
- BNTC 5
- IMAB 5
- Target Price
- BNTC $24.80
- IMAB $6.80
- AVG Volume (30 Days)
- BNTC 36.4K
- IMAB 1.8M
- Earning Date
- BNTC 11-13-2025
- IMAB 11-02-2025
- Dividend Yield
- BNTC N/A
- IMAB N/A
- EPS Growth
- BNTC N/A
- IMAB N/A
- EPS
- BNTC N/A
- IMAB N/A
- Revenue
- BNTC N/A
- IMAB N/A
- Revenue This Year
- BNTC N/A
- IMAB N/A
- Revenue Next Year
- BNTC N/A
- IMAB N/A
- P/E Ratio
- BNTC N/A
- IMAB N/A
- Revenue Growth
- BNTC N/A
- IMAB N/A
- 52 Week Low
- BNTC $8.20
- IMAB $0.60
- 52 Week High
- BNTC $17.15
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- BNTC 57.09
- IMAB 44.24
- Support Level
- BNTC $13.49
- IMAB $3.20
- Resistance Level
- BNTC $14.05
- IMAB $4.64
- Average True Range (ATR)
- BNTC 0.56
- IMAB 0.41
- MACD
- BNTC -0.01
- IMAB -0.17
- Stochastic Oscillator
- BNTC 64.92
- IMAB 24.39
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).